Bronchiectasis Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Canada, China - Size and Forecast 2024-2028

Bronchiectasis Drugs Market Size 2024-2028

The bronchiectasis drugs market size is estimated to increase by USD 394.1 million, at a CAGR of 10.87% between 2023 and 2028. The market's expansion is influenced by several factors, including the increasing prevalence of risk factors associated with the condition, the availability of low-cost off-label generics, and the growing population of elderly individuals. However, challenges persist due to the lack of approved medications for the disease, underdiagnosis rates, and the preference for alternative treatment options. Despite the prevalence of risk factors driving demand, the absence of approved drugs remains a hurdle, along with issues related to underdiagnosis. Additionally, the availability of low-cost generics offers some relief, but alternative treatments still attract attention. As the geriatric demographic continues to grow, there's a pressing need for effective medications and improved diagnosis methods to address the rising demand and challenges associated with this market.

What will be the size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

By Product

The market share growth by the antibiotics segment will be significant during the forecast period. This segment consists of a wide range of off-label drugs, such as azithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and macrolides, which are used for the treatment. Due to the absence of approved drug therapy for bronchiectasis, these antibiotics are very common in use.

Get a glance at the market contribution of various segments View the PDF Sample

The antibiotics segment ?was valued at ?USD 241.90 million?in 2018. The treatment with antibiotics is broadly classified as exacerbation treatment, chronic suppressive treatment, and eradication treatment.  Antibiotic resistance in patients poses a challenge to the growth of the segment. A single antibiotic may not be able to inhibit all pathogens present and near the respiratory tract, even if every pathogen associated with the respiratory system is resistant to various antibiotics. Therefore, in order to attain the aim of a clinically meaningful result, different antibiotics must be used with each other. Hence, such factors are fuelling the growth of this segment during the forecast period.

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In this region, the increasing sales of various off-label drug therapies approved for other chronic respiratory conditions and the increasing prevalence of chronic respiratory diseases have fueled the growth of the market. The Market is experiencing significant growth due to various factors, including the increasing prevalence of bronchiectasis, advancements in drug development, and rising awareness of this respiratory condition. The healthcare systems of different countries are recognizing the importance of addressing unmet medical needs in the treatment of bronchiectasis, particularly idiopathic bronchiectasis. Hence, such factors are driving the market in North America during the forecast period.

Market Dynamics and Customer Landscape

In addressing conditions like chronic lung disease and respiratory problems, the market relies on advancements in technology for illness diagnostics and targeted therapies. Awareness initiatives by organizations like the American Thoracic Society promote understanding among smokers and drinkers. While generic medications, and otolaryngologists offer affordable options, telemedicine bridges gaps in access. However, challenges persist, including high healthcare costs and trade regulations, underscoring the importance of continued innovation in treating bronchiectasis. Bronchiectasis, often associated with respiratory problems and chronic lung disease, necessitates effective treatments. Medical advancements, including targeted therapies and telemedicine, offer hope. Awareness initiatives by organizations like the American Thoracic Society raise awareness. Despite high healthcare costs, access to generic medications and technology for illness diagnostics is vital. However, challenges such as trade regulations persist. The market for bronchiectasis drugs caters to the needs of smokers and drinkers seeking relief and improved quality of life.

Key Market Driver

The driving force behind the growth of the market lies in the escalating cases of associated risks, which are contributing to the increasing prevalence of bronchiectasis globally. This condition often arises from underlying health issues such as humoral immunodeficiency, inflammatory bowel diseases, rheumatologic diseases, COPD, and cystic fibrosis, all of which are of significant concern worldwide.

Additionally, external factors such as occupational exposure to poisonous gases, rising air pollution levels, and increasing smoking habits are further fueling the incidence of bronchiectasis. As the number of diagnosed cases continues to rise, the demand for effective treatment options becomes imperative, driving the market's growth trajectory. Consequently, the multitude of etiological factors underlying bronchiectasis is expected to positively impact the global market in the forecast period.

Significant Market Trends

The growing awareness about bronchiectasis is the primary trend in the market. Bronchiectasis is often misunderstood as a common cough and cold, as the symptoms of most respiratory tract infections are overlapped. This results in underdiagnosing the infection, which reduces the use of treatment options and thus affects the growth of the market. In order to increase the prevalence of this disease, primary and secondary healthcare centers need to be better informed about it. 

Many awareness programs have been put in place by a number of public and private organizations across the world to inform people about this. In addition, some companies are regularly organizing educational programs to inform healthcare professionals and patients of available therapeutic options for the treatment of bronchiectasis. Such awareness programs about the medications available for the treatment of bronchiectasis are expected to positively impact the market during the forecast period.

Major Market Challenge

The lack of approved drugs for bronchiectasis is the major challenge to the growth of the global bronchiectasis drug market. The treatment options for bronchiectasis consist of medications, CPT, the use of lung airway devices, oxygen therapy, and surgery.  The reason for the infection in bronchiectasis can be different, but a wide range of treatments is required in some cases. There are no authorized products in the global bronchiectasis drug market at present. However, drugs are used as OTC and off-label drug therapies largely to relieve the symptoms of other conditions, thus increasing the risk of bronchiectasis. However, human use of antibiotics category leads to a process of drug resistance.

Moreover, patient adherence to treatment continues to decline as a result of resistance to antibiotics. The growth of the market is projected to be limited due to the lack of availability of approved medicinal products, along with a weak therapeutic effect of Symptomative Medicines. In addition, there are only a few drugs available for the treatment of bronchiectasis. Also, R&D is focused more on the development of substitute therapies. Thus, the lack of approved drug therapies is expected to hinder the growth of the market in focus during the forecast period

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Who are the Major Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product launches, to enhance their presence in the market.

AbbVie Inc.: The company offers breast cancer therapeutics such as Veliparib, a PARP inhibitor.

The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including

• Akorn Operating Co LLC
• Amneal Pharmaceuticals Inc.
• Aurobindo Pharma Ltd.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr Reddys Laboratories Ltd.
• Endo International Plc
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Lupin Ltd.
• Neopharma Corp.
• Pfizer Inc.
• Reckitt Benckiser Group Plc
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Virtus Pharmaceuticals LLC
• Wockhardt Ltd.
• Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2023 to 2028, as well as historical data from 2018 to 2022 for the following segments.

• Product Outlook 
  • Antibiotics
  • Expectorants
  • Others
• Distribution Channel Outlook 
  • Online
  • Offline
• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Australia
    • Argentina
    • Rest of World

You may also interested in below market reports:

• Geriatric Medicines Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, China, India - Size and Forecast 
• Pneumonia Testing Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, Germany, UK, Japan - Size and Forecast 
• Pulmonary Arterial Hypertension (PAH) Drugs Market by Route of Administration, Action Mechanism, and Geography - Forecast and Analysis 

Market Analyst Overview

The market addresses the treatment of bacterial lung infections, which can be caused by various factors such as bacterial load and disease phase. Pulmonologists utilize tools like High-Resolution Computed Tomography (HRCT) for accurate diagnosis and monitoring. The market landscape depends on the Bacterial lung infection, Cause of infection, API, Bronchiectasis incidence, Bronchial tubes, Inflammation, Mucolytics, Inhaled corticosteroids, Bronchodilators, Exacerbations, Lung function, New drugs, Collaborations, Healthcare providers, Lung health organizations, World Bronchiectasis Day, Unmet medical needs, Idiopathic bronchiectasis. Treatment options include generic drugs and branded drugs, each containing Active Pharmaceutical Ingredients (APIs) targeted at reducing bacterial load and improving therapeutic adoption rates.

In underdeveloped regions, the prevalence of bronchiectasis and the demand for low-priced drugs underscore the need for accessible treatment options. Incidence rates influence patient population demographics, driving research into new and innovative drugs tailored for personalized treatment approaches. Development activities focus on regulatory approvals and securing reimbursements within healthcare systems, facilitating access to advanced therapies. Advancements in drug formulations and improved diagnostics cater to rising awareness among aging populations about bronchiectasis management. The market's growth is propelled by continuous advancements in medical science and the pharmaceutical industry's commitment to enhancing patient outcomes in managing bacterial lung infections associated with bronchiectasis.

View PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2028.
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch